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1. Introduction and Background
Since the pioneering work of Alexander Fleming, Paul
Ehrlich, Gerhard Domagk, and others on antibiotics about
100 years ago, the benefits of these “miracle drugs” for the
treatment of infectious diseases have been taken for granted
in public health. Unfortunately, a dramatic change has taken
place in recent years in terms of the efficacy of administered
antibiotics. More and more bacteria have developed resist-
ance against antibiotics, and these resistant microorganisms
can withstand attack by antimicrobial drugs so that standard
treatments become ineffective and infections persist, thereby
increasing the risk of spreading to others.[1]
The evolution of resistant strains is a natural phenomenon
that occurs through selection pressure on the microorganism
population from the antibiotic. There are currently five main
targets for antibiotics, and antibiotic resistance can essentially
be acquired through four different pathways and expressed by
four different mechanisms (Figure 1).
The use and misuse of antimicrobial drugs accelerates the
emergence of drug-resistant strains. According to the World
Health Organization (WHO), there were about 480000 new
cases of multidrug-resistant tuberculosis (MDR-TB) in 2013
and extensively drug-resistant tuberculosis (XDR-TB) has
been identified in 100 countries.[1] There are high proportions
of antibiotic resistance in bacteria that cause common
infections (e.g., urinary tract infections, pneumonia, blood-
stream infections) in all regions of the world. A substantial
percentage of hospital-acquired infections are caused by
highly resistant bacteria such as methicillin-resistant Staph-
ylococcus aureus (MRSA), vancomycin-resistant enterococci
(VRE), or multidrug-resistant Gram-negative bacteria that
are resistant to all b-lactam antibiotics.
Patients with infections caused by drug-resistant bacteria
are generally at increased risk of worse clinical outcomes and
death, and they consume more health-care resources than
patients infected with the same bacteria that are not
resistant.[1]
Owing to the discovery gap during the last decades for
novel antibiotic chemotherapies in the pharmaceutical indus-
try and to the occurrence of bacterial strains resistant to the
current antibiotics, public health is running out of treatment
options for dealing with infectious diseases. In order to
respond to this emerging crisis, global organizations such as
the WHO have urged the scientific community to search for
new approaches to combat antibiotic resistance.
Antibiotic drug discovery is hampered by several intrinsic
factors. For instance, the permeability barrier provided by the
outer membrane of Gram-negative bacteria typically leads to
more resistant strains compared to Gram-positive bacteria.
Since the outer membrane hinders the antibiotics from
gaining access to their targets inside the bacterial cell, the
development of antibiotics to treat infections caused by
Gram-negative bacteria remains a challenge. In this regard,
cationic peptides can increase the permeability of the outer
membrane and allow antibiotics to reach their target inside
the bacterial cell.[2] Another important aspect of antibiotic
drug discovery is the lack of novel antibacterial targets. In
addition to the well-understood and heavily exploited anti-
bacterial targets such as cell wall synthesis or protein syn-
thesis, new targets or modes of action are desperately needed.
Recently, targeting adenosine triphosphate (ATP) synthase
has been a successful step forward for the treatment of drug-
resistant strains of Mycobacterium tuberculosis.[3] More
examples with novel modes of action, such as targeting
antibiotic resistance at the genetic level, will be discussed in
this Review.
A lot of the research for new antibiotics is still focused on
developing improved versions of existing molecules. While
some of these are simply “me-too” versions of drugs with only
Finding strategies against the development of antibiotic resistance is
a major global challenge for the life sciences community and for public
health. The past decades have seen a dramatic worldwide increase in
human-pathogenic bacteria that are resistant to one or multiple anti-
biotics. More and more infections caused by resistant microorganisms
fail to respond to conventional treatment, and in some cases, even last-
resort antibiotics have lost their power. In addition, industry pipelines
for the development of novel antibiotics have run dry over the past
decades. A recent world health day by the World Health Organization
titled “Combat drug resistance: no action today means no cure
tomorrow” triggered an increase in research activity, and several
promising strategies have been developed to restore treatment options
against infections by resistant bacterial pathogens.
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moderately better activity, some have been developed
through logical and systematic changes that make them
more efficient or less susceptible to resistance mechanisms.
Screening for novel antibiotics from natural sources is
another way to broaden our possibilities for treating infec-
tions, but this does not eliminate the intrinsic risk for the
development of resistance to these novel antibiotics. A
mechanistic and structural understanding of bacterial resist-
ance offers much better opportunities for tackling this
problem because this allows the origin of the problem to be
addressed rather than simply generating additional resistance
in the future. Combining mechanistic information on resist-
ance with rational structure-based drug discovery approaches
enables antibiotic resistance to be bypassed or even sup-
pressed. This strategy has been applied lately with increasing
success and will be the focus of this Review.
Structure-based design has developed into a mature
technique in drug discovery. This has been fueled by
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Figure 1. The four resistance acquisition pathways, the four main mechanisms of resistance, and the five main targets for antibiotics.
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a tremendous amount of crystallographic structural data for
biological target macromolecules and backed up by genomics
data from sequencing campaigns. Once the structure of
a target or a co-crystal structure of a target together with
a bound ligand is available, structure-based design can be
applied both rationally and creatively in order to tailor the
properties of a drug molecule. Fragment-based approaches
are used for the identification of chemical starting points for
lead optimization, virtual docking allows in silico screening,
and de novo approaches generate new chemotypes for drug
molecules.[4–8]
Several excellent and comprehensive review articles
about antibiotics have appeared in this journal as well as
others. Their focus has been, among other things, on the
discovery and synthesis of antibiotics and on the evolution of
antibiotic resistance.[9–13] In this Review, we highlight struc-
ture-based approaches that have successfully been applied to
combat antibiotic resistance. This includes several target
classes and different structure-based techniques in order to
depict the broad applicability of this strategy. Our selection is
predominantly based on examples that have already delivered
clinical drug candidates and can serve as showcase projects for
the antibiotic research community. In addition, we have also
included the results of very recent collaborations in this field
that have not yet delivered clinical candidates, but have
delivered promising techniques and scientific concepts in
order to stimulate the scientific discussion.
Owing to the high amount of structural data in this
Review, the preparation of this manuscript required heavy
use of graphics and modeling software. For the depiction of
co-crystal structures and structural models, we used Chimera
1.10.1[14] along with Inkscape[15] for labeling. Molecular
docking was done with AutoDock Vina 1.1.2.[16]
2. Protein Synthesis Inhibitors
The bacterial protein synthesis machinery is a major
target for antibiotics and it has been used for efficient
structure-based interventions against antibiotic resist-
ance.[17,18] Protein synthesis, which is conducted by ribosomes,
converts mRNA into the corresponding polypeptide chain.[19]
This process can be divided into four steps: initiation,
elongation, termination, and recycling. The first two are de-
picted in Figure 2 and will be described here briefly because
they provide several targets for antibiotic intervention.
Bacteria have 70S ribosomes that are made up of two
subunits.[19–22] The large 50S subunit, which includes the 23S
and 5S rRNAs, binds aminoacyl tRNA (aa-tRNA), catalyzes
peptidyl transfer, and controls the elongation process, while
the smaller 30S subunit, which includes the 16S rRNA, binds
mRNA and initiates protein synthesis. The initiation step
involves assembling these two subunits around the mRNA
and the initiator fMet-tRNA. This process is catalyzed by
three prokaryotic initiation factors: IF1, IF2 and IF3. The
resulting 70S initiation complex has three main tRNA binding
sites, the A, P, and E sites. The A site is the site at which the
charged aminoacyl-tRNA matching the mRNA codon enters
the ribosome. The P site carries the peptidyl-tRNA, the
tRNA carrying the growing peptide chain. The E site harbors
the deacylated or uncharged tRNA before it exits the
ribosome. The elongation step is the cycle that adds amino
acids to the growing peptide chain in a stepwise manner and
can be considered the heart of protein synthesis. In the first
step, a ternary complex composed of aa-tRNA, the elongation
factor Tu, and guanosine triphosphate (aa-tRNA·EF-
Tu·GTP) binds at the A site. After successful decoding, the
complex is hydrolyzed, thereby resulting in the departure of
EF-Tu·GDP (GDP: guanosine diphosphate) and an inorganic
phosphate (Pi), which allows the aa-tRNA to enter the A site
and bind. Peptide bond formation then occurs through
transfer of the entire peptide chain from the peptidyl-tRNA
in the P site to the aa-tRNA in the A site. This pre-
translocation ribosomal state (PRE state) is often referred
to as a hybrid state since the tRNAs are moving back and
forth between the A/A, P/P, A/P and P/E sites. In the next
step, elongation factor G (EF-G) catalyzes translocation of
the tRNA2·mRNA complex by a distance of one codon
(POST state). This results in the deacylated tRNA being
moved to the E site, the peptidyl-tRNA being moved to the
P site, and the A site becoming free to bind the next aa-tRNA.
Until a stop codon enters the A site, this cycle continues,
gradually building the full peptide chain. As seen in Figure 2,
protein synthesis is targeted by a number of different classes
of antibiotics at essentially every step of the process. While
some classes of antibiotics such as macrolides, oxazolidinones,
and pleuromutilins bind the large 50S subunit, others such as
aminoglycosides and tetracyclines interfere with the smaller
30S subunit.
2.1. Oxazolidinones
Oxazolidinones are the only new class of synthetic
antibiotics to be discovered and introduced into the clinic
over the past 50 years.[23] They were first discovered in 1978
(E. I. duPont de Nemours & Co.)[24] but later abandoned
owing to serious toxicity issues.[25] Research continued in this
area (initiated by Upjohn, later Pharmacia, now Pfizer Inc.),
and by 1996, two nontoxic oxazolidinones, linezolid and
eperezolid, had been developed (1 and 2 ; Figure 3).[26]
These two molecules were the results of a wide structure–
activity relationship (SAR) study that revealed the required
Rainer Riedl studied chemistry at the Univer-
sity of Heidelberg and received his Ph.D. in
organic chemistry from the University of
Cologne with Prof. Berkessel in 1998, before
pursuing postdoctoral studies in chemical
biology with Prof. Schultz as a Humboldt
fellow at UC Berkeley and The Scripps
Research Institute, La Jolla, CA, USA. He
then joined Eli Lilly for drug discovery proj-
ects on cancer, inflammatory diseases, and
diabetes. Since 2009, he has headed the
Center for Organic and Medicinal Chemistry
at ZHAW, focusing on structure-based treat-
ment options for unmet medical needs with
an emphasis on infectious diseases.
Angewandte
ChemieReviews
6603Angew. Chem. Int. Ed. 2016, 55, 6600 – 6626 Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
substitution on the central oxazolidinone core.[27] Essential
factors for antibacterial activity were the N-aryl substituent,
the 5S configuration, and the C5 acylaminomethyl group. The
meta-fluoro substitution of the phenyl ring was not essential,
but usually helped to increase activity, and the para-substi-
tution could be varied to expand the antibacterial spectrum.
While oxazolidinones are protein synthesis inhibitors that
bind to the ribosome, it has taken a number of years to
identify the binding site and most likely mode of action.[28] In
2008, two reported X-ray co-crystal structures of linezolid
bound to 50S ribosomal subunits confirmed the previously
established site of action and suggested a mode of action
(Figure 4).[29,30]
Linezolid binds to the A-site pocket of the 50S subunit at
the peptidyl transferase center (PTC) in actively translating
bacterial ribosomes and interferes with binding of the charged
aminoacyl tRNA. Specifically, linezolid binds to a pocket
formed by eight RNA residues, one of which, U2585Ec, is
stabilized in a distinct conformation. By stabilizing U2585Ec
in a nonproductive conformation, linezolid affects the binding
and/or positioning of the initiator-tRNA and prevents the
Figure 2. The mechanism of bacterial translation. Antibacterial targets highlighted.
Figure 3. Structures of the first two oxazolidinones synthesized by
Upjohn.
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binding of tRNA at the A site, thereby halting the translation
sequence (Figure 4A).[29]
Resistance to oxazolidinones is still relatively rare. So far,
three classes of oxazolidinone resistance mechanisms have
been characterized.[31] The first involves mutations in the 23S
rRNA central loop of domain V, the peptidyl transferase
center. While some of the mutated residues interact directly
with the oxazolidinone, many do not but are instead used to
stabilize the region surrounding the oxazolidinone.[28] Muta-
tions in these residues lead to small conformational changes
of the linezolid binding pocket, which adversely affects drug
binding. The second mechanism, which is less common,
involves mutations in the genes rplC and rplD, which encode
ribosomal proteins L3 and L4, respectively.[31]
Beyond these chromosomally encoded point mutations,
the last mechanism involves acquisition of the ribosomal
methyltransferase gene cfr (chloramphenicol-florfenicol
resistance). This resistance is more worrisome than the
mutation-based mechanism since it is horizontally transfer-
able and carries a low fitness cost.[32,33] Mechanistically, the
methyltransferase Cfr, through C8 methylation of the key
residue A2503Ec in the 23S rRNA, greatly reduces suscept-
ibility to a wide range of ribosome-targeting antibiotics,
including amphenicols, lincosamides, pleuromutilins, strep-
togramin A, 16-membered macrolides, and linezolid.[34] As
seen in Figure 4B, the addition of a methyl group on A2503Ec
leads to a steric clash with the acetamide group of linezolid,
thereby causing a two- to eight-fold increase in the minimum
inhibitory concentration (MIC).[36] Since the discovery of
linezolid, over 30 companies have advanced more than
a dozen candidates in clinical development. Unfortunately
most of these have failed owing to issues related to
pharmacokinetic (PK) properties, safety profile, solubility,
or lack of improvement of antimicrobial activity over line-
zolid. Therefore the two main challenges for successful
second-generation oxazolidinones are minimizing the myelo-
suppression safety signal and achieving adequate activity
against linezolid-resistant strains of bacteria.[31] Two second-
generation oxazolidinones that attempt to solve these prob-
lems in a rational way will be presented herein.
2.1.1. Tedizolid
Tedizolid phosphate (3 ; previously torezolid phosphate,
TR-701, DA-7218) is the inactive prodrug of tedizolid (4 ;
previously torezolid, TR-700, DA-7157, which was discovered
by Dong-A Pharmaceuticals, and developed by Trius Ther-
apeutics and Cubist Pharmaceuticals).[37, 38] After two success-
ful phase III trials, tedizolid was approved by the Food and
Drug Administration (FDA) in June 2014 under the trade
name Sivextro for the treatment of MRSA skin infections
(Figure 5).
Structurally, tedizolid presents two main differences
compared to linezolid: substitution of the acylaminomethyl
group at C5 by a hydroxymethyl moiety and introduction of
the C/D ring system, here a 6-(2-methyl-2H-tetrazol-5-
yl)pyridine (Figure 5). The increase in lipophilicity brought
by the addition of the C and D rings obliged the medicinal
chemists to find an adequate prodrug that would solve the low
aqueous solubility and oral bioavailability problems.[37] A
series of formulations was evaluated and the monophosphate
ester was found to have the best properties (high water
solubility and improved bioavailability) while also masking
the primary alcohol, which provided a greatly improved
monoamine oxidase inhibition profile.[31]
The effect that these structural modifications bring to
tedizolid can be clearly seen in Figure 6. At the bottom end of
the binding site, the methylated A2503Ec is able to accom-
modate the sterically compact hydroxymethyl group while
still maintaining the hydrogen bonding with G2505Ec. Addi-
tionally, the proposed binding model predicts two new
Figure 4. A) Co-crystal structure of linezolid (1; C green, F purple) in
the 50S ribosomal subunit from Haloarcula marismortui (PDB ID:
3CPW). B) A model of linezolid (1) in the 50S ribosomal subunit from
H. marismortui that has been methylated by Cfr at A2503Ec. The
surface clash is highlighted in red. Escherichia coli numbering in
parentheses. Model was generated with Chimera 1.10.1 according to
K. J. Shaw et al.[14, 35]
Figure 5. Structures of tedizolid phosphate, tedizolid, and radezolid
compared to linezolid.
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stabilizing hydrogen bonds between the C/D ring system and
the backbone ribose sugars of A2451Ec and U2584Ec.
In a study of its activity against linezolid-resistant staph-
ylococci, tedizolid showed a more than 16-fold improvement
compared to linezolid.[39] It also maintained activity against
most of the tested isolates, including multidrug-resistant ones,
thus clearly demonstrating the benefit of the structure-based
approach.
2.1.2. Radezolid
Radezolid (5 ; previously RX-1741 and Rx-01_667;
Figure 5) is a fully synthetic oxazolidinone (developed by
Melinta Therapeutics, formerly Rib-X) that has completed
two phase II clinical studies.[40] Radezolid is the result of
a program developed to expand the spectrum of oxazolidi-
nones to Gram-negative bacteria and optimize drug-like
properties.[41] The program started with the observation that
linezolid and sparsomycin (6, a non-selective antibiotic) had
overlapping binding sites within the peptidyl transferase
center of the 50S ribosomal unit (Figure 7).[42,43]
The strategy was therefore to link the two molecules
together via an adequate bridging element and make the
required structural modifications on the sparsomycin side to
increase potency and selectivity.[41,44] Figure 8 shows two (7
and 8) of the numerous bridged antibiotics that were
synthesized on the road to radezolid and clearly shows the
evolution of the western half and the bridging unit.
Once the optimal structural elements were determined,
the activity of radezolid was assessed and it was found to bind
with higher affinity to the ribosome than linezolid, which gave
it enhanced antibacterial activity (2–8-fold improvement over
linezolid) against various Gram-positive pathogens.[45] Struc-
ture–activity studies of diverse oxazolidinones revealed that
despite the presence of a C5 acylaminomethyl group in
radezolid, it retains activity against the clinical cfr-positive
CM05 strain of S. aureus with a minimal inhibitory concen-
tration (MIC) value of 2 mgmL¢1, which is between those of
tedizolid (0.5 mgmL¢1) and linezolid (8 mgmL¢1). This is most
likely due to additional binding interactions of the C/D ring
system with the PTC, far from the ribosomal modifications
that lead to resistance to linezolid, including the cfr-mediated
methylation of A2503Ec.[36,40, 46] Most noteworthy is the fact
that the spectrum could be expanded to Gram-negative
organisms such as Haemophilus influenzae and Moraxella
catarrhalis. Additional features of radezolid, besides over-
coming the ribosomal mutation resistance, include a 100-fold
decreased activity in inhibiting translation in rabbit reticulo-
cytes than in S. aureus ribosomes and interaction with
U2585Ec, as verified by biochemical assay.[40]
2.2.Macrolides
Macrolides are a family of 14-, 15-, and 16-membered
polyketide lactone rings with one or more neutral or amino
sugar substituents at various positions (Figure 9).[47] Eryth-
Figure 6. Models of tedizolid (4) (C green, F purple) in A) the 50S
ribosomal subunit from H. marismortui (PDB ID: 3CPW) and B) the
50S ribosomal subunit from H. marismortui that has been methylated
by Cfr. Even with methylation at A2503Ec, tedizolid (4), unlike line-
zolid, is able to bind to the ribosomal RNA. E. coli numbering in
parentheses. Models generated with Chimera 1.10.1 and AutoDock
Vina 1.1.2 according to K. J. Shaw et al.[14, 16, 35]
Figure 7. Overlay of sparsomycin (6) (C orange) and linezolid (1; C
green, F purple) in the 50S ribosomal subunit of H. marismortui
(PDB IDs: 1M90, 3CPW).
Figure 8. Structures of sparsomycin, linezolid, and molecules devel-
oped on the way to radezolid.
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romycin (9), the first and prototypical macrolide, was isolated
from actinomycete bacteria in 1949.[48] It was first used
clinically in the early 1950s, but owing to its acid instability,
second-generation semisynthetic macrolides such as clari-
thromycin (10)[49] or azithromycin (11)[50] were developed
(Figure 9). Subsequently, owing to the emergence of resist-
ance to first- and second-generation macrolides, a third
generation, coined the ketolides, was developed. In these
14-membered lactone rings, the cladinose sugar at C3 is
replaced by a ketone moiety, C11 and C12 are now part of an
oxazolidinone ring, and an alkyl-aryl side chain is appended
to the macrolactone core. Telithromycin (12) is the only
registered ketolide to date (Figure 9).
Like many other antibiotic classes, macrolides are bacteri-
ostatic. They bind to the 50S ribosomal subunit in the vicinity
of the peptidyl transferase center just above the constriction
formed by the extended loops of ribosomal proteins L4 and
L22 and were originally thought to inhibit protein synthesis by
completely obstructing the ribosomal tunnel.[51] In fact,
modeling studies have shown that even with a bound macro-
lide, the tunnel can still accommodate a nascent peptide
chain. The macrolide nevertheless greatly hinders the pro-
gression of the peptide, which is usually dissociated by the
peptidyl-tRNA drop-off mechanism before reaching its full
size.[51, 52] Macrolides have also been shown to block the
formation of the large 50S ribosomal subunit by binding to its
precursors.[53]
A number of co-crystal structures of macrolides bound to
the ribosome have been published and they show that the
main component in the binding pocket is A2058Ec.[54–56] Key
interactions include polar contacts between the functional
groups of the C5 desosamine sugar and residues A2058Ec and
A2059Ec, as well as hydrogen bonds between the three
lactone hydroxy groups and the 50S ribosomal subunit
(Figure 10).
Bacteria have developed a number of mechanisms of
resistance to macrolides.[57] Even though the majority of them
involve alterations at the ribosomal target site, substrate
inactivating enzymes (mainly esterases) and efflux mecha-
nisms have also been reported. Alteration of ribosomal
binding sites usually leads to failure of the antibiotic to bind,
which in turn disrupts its ability to inhibit protein synthesis. In
the case of macrolide resistance, these alterations mainly take
place in one of two ways. The first, which has the smallest
effect, is modification of the ribosomal proteins L4 and L22 at
the end of their hairpin structures, close to the binding site.[58]
Interestingly, mutations at L4 lead to large reductions in the
binding affinity while the L22 mutants show no change in the
binding constant but still confer resistance. This is explained
by a widening of the tunnel, which allows passage of the
peptide without affecting the binding.[59] The second and most
common resistance mechanism is modification of the rRNA.
This takes place, unsurprisingly, on A2058Ec, the key
component of the binding pocket. Mono and dimethylation
of A2058Ec are carried out by erythromycin ribosome
methylation (Erm) methyltransferases.[60] While monomethy-
lation confers only moderate resistance to macrolides and
none to ketolides, dimethylation leads to complete blocking
of the binding site and high resistance to both macrolides and
ketolides.[18,61] Mutation of A2058Ec into G2058Ec also
induces resistance owing to the similar increase in steric
bulk. Notably, in archaea and eukaryotes, position 2058Ec is
naturally a guanine, which explains the selectivity for
bacteria.[62]
As mentioned earlier, ketolides were developed in an
effort to counter resistance to macrolides. Their key features
include a 14-membered macrolactone, the replacement of the
C3 cladinose sugar by a keto group, a cyclic carbamate and an
extended alkyl-aryl side chain (Figure 11). The C3 keto group
gives rise to potent activity against strains with Erm-mediated
inducible resistance and surmounts resistance through
efflux.[63] It also removes some of the steric hindrance
around the desosamine sugar, which allows it to reposition
itself when binding to monomethylated ribosomes.[64] The
Figure 9. Structures of the three macrolides erythromycin, clarithromy-
cin, and azithromycin, as well as the ketolide telithromycin.
Figure 10. Overview of the binding mode of erythromycin (9 ; C green)
to the 50S ribosomal subunit (PDB ID: 1JZY) from Deinococcus radio-
durans. The nucleotides are labeled according to D. radiodurans (E. coli
in parentheses).
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cyclic carbamate introduces additional interactions with the
ribosome, which stabilize the conformation of the core
macrolide and lead to potent antibacterial activity.[65] Crystal
structures of ketolides in both D. radiodurans and in H.
marismortui have been published and show notable differ-
ences in their binding modes.[51,56, 66,67] Indeed, when com-
plexed to the ribosome of H. marismortui, the side chain of
telithromycin resides over the plane of the macrolactone ring
(PDB ID: 1YIJ)[56] whereas with the ribosome of D. radio-
durans, the side chain points away from the macrolactone
core (PDB ID: 1P9X).[66] This clearly highlights the impor-
tance of crystallographic data and is a good reminder to
exercise caution when using models. Nevertheless, the
common feature is that the ketolides not only bind to
domain V in a similar fashion as macrolides, but their
elongated side chains engage in additional interactions in
domain II. This results in tighter binding and allows them to
compensate for modifications in domain V resulting from
mutation or methylation.
Telithromycin (12) is currently the only ketolide on the
market, but following safety controversies, it has been
partially withdrawn.[68] Its use has been associated with
severe hepatotoxicity along with blurred vision and serious
cases of liver failure.[69] These are believed to result from
inhibition of the nicotinic acetylcholine receptors. The
pyridine ring in the extended side chain of telithromycin has
been suggested to be the culprit.[70] New ketolides lacking this
problematic pyridine ring are currently being investigated.
2.2.1. Solithromycin
Solithromycin (13 ; previously CEM-101, developed by
Cempra) is a 2-fluoroketolide currently undergoing phase III
clinical trials. As seen in Figure 11, solithromycin is very
similar to telithromycin, with only two minor modifications.
The first is replacement of the aforementioned problematic
imidazolyl pyridine with a triazolyl aniline, and the second is
the introduction of a fluorine atom at the C2 position.
Removal of the imidazolyl pyridine resulted in a 30-fold
reduction in the inhibition of nicotinic acetylcholine receptors
compared to telithromycin.[70] As mentioned earlier, previous
X-ray structures of ribosome-bound ketolides showed very
different orientations of their alkyl-aryl side chains depending
on the bacterial species. Therefore, questions remained as to
the actual binding mode of solithromycin and telithromycin in
pathogenic bacteria. In 2010, Cate, Mankin, and co-workers
crystallized solithromycin as well as telithromycin in complex
with the E. coli ribosome and were able to indicate that the
placement of these ketolides most likely reflects the binding
in S. aureus ribosomes given the sequence conservation of the
A752:U2609 base pair among many eubacteria.[71, 72]
These crystal structures delivered revealing insight into
various aspects of the interaction (Figure 12). A stacking
interaction can be seen with the A752:U2609 base pair, which
is present in the ribosome of E. coli and many other
pathogenic bacteria. The aniline moiety, which replaces the
detrimental pyridine is shown to form additional hydrogen
bonds, notably to A752 and G748, and results in tighter
binding. Finally the fluorine atom at the C2 position was
shown to contribute to drug binding as well as chemical
properties such as solubility and cellular uptake.[73] Indeed, in
comparison to non-fluorinated analogues, the fluorinated
versions showed stronger inhibition of the growth of strepto-
cocci carrying the erm gene. Interestingly, for solithromycin,
weak binding to ribosomes dimethylated at A2058Ec could be
detected by chemical probing.[71] Key structural features of
Figure 11. Structures of the ketolides telithromycin and solithromycin.
Figure 12. Overlay of telithromycin (12 ; C green, PDB ID: 4V7S) and
solithromycin (13 ; C yellow, F purple) in the 50S ribosomal subunit
(PDB ID: 4WWW) from E. coli. Nucleotides are labeled using the E.
coli numbering system.
Figure 13. Structure–activity relationships of ketolides.
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the ketolides are summarized in Figure 13 (for an example of
a ketolide with a 6-O-attached side chain, see cethromy-
cin).[74,75]
2.3. Thiopeptides
The thiopeptides are a family of highly modified sulfur-
rich macrocyclic peptides (Figure 14, numbering according to
thiomuracin A),[76] which have been isolated from diverse
sources such as soil bacteria and marine samples.[77] While
there are now over 100 known thiopeptides, the first member,
micrococcin P1 (14), was isolated in 1948.[78] These molecules
are of ribosomal origin, are highly posttranslationally pro-
cessed, and feature a characteristic macrocyclic core consist-
ing of multiple thiazoles and a 6-membered nitrogen-con-
taining heterocycle, which can be found in different oxidation
states. While thiopeptides are a new class of antibiotics with
a novel mechanism of action, their use as an antibiotic
treatment option has been hampered by their very large
molecular size and poor aqueous solubility. Thiopeptides are
inhibitors of protein synthesis, but their mode of action differs
depending on the size of the macrocycle. Thiostrepton A
(15),[79] the archetypal thiopeptide, and micrococcin P1 pos-
sess 26-memberedmacrocyclic cores and are known to bind to
the GTPase-associated region of the ribosome/L11 protein
complex.[80] Thiopeptides with 29-membered macrocyclic
cores such as GE2270 A (16), on the other hand, interact
with GTP-bound bacterial EF-Tu, preventing the formation
of the ternary complex with aa-tRNA.[81]
GE2270 A was isolated in 1991 by scientists at Lepetit
Research Institute.[82] Although the in vitro activity of this
compound was shown to be excellent against MRSA, VRE,
and streptococci, poor aqueous solubility prevented further
development.[83] Two derivatives are currently being inves-
tigated.
2.3.1. LFF571
In order to increase the water solubility of GE2270 A, the
unstable oxazoline side chain was replaced with solubilizing
functional groups (Novartis). The 4-aminothiazolyl moiety
was chosen as a starting point and a wide variety of amines
and acids linked via different spacers were synthesized.[83–85]
Guided by co-crystal structures with EF-Tu, this search led to
the discovery of two potent analogues with cyclohexylcarbox-
ylic acid side chains residing in proximity to the Arg223
residue of EF-Tu.
Figure 14. Structures of thiopeptides.
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These compounds were then improved by the addition of
a second solubilizing group.[86] Taking into account the
position of Arg262, a large variety of differently linked
acids were synthesized. It was found that a pentanoic acid
residue appended onto the aminothiazole was the best since it
placed the acid in proximity to this residue (Figure 15). The
resulting compound, named LFF571 (17), also showed very
high aqueous solubility (> 10 mgmL¢1). Triacid-containing
analogues were also synthesized but these both failed to yield
additional benefits and greatly increased the synthetic com-
plexity, and they were therefore not pursued. LFF571 is
currently undergoing phase II clinical trials against C. difficile
infections.
2.3.2. NVP-LDU796
In 2009, the isolation of thiomuracins, a novel class of
antibiotic thiopeptides, was reported (Novartis).[76] These
secondary metabolites, which are produced by a strain of
Nonomuraea, are structurally related to GE2270 A and share
the same mechanism of action, namely binding to EF-Tu. The
thiomuracins show potent antibiotic activity against MRSA
and VRE, with minimum inhibitory concentrations below
1 mgmL¢1. Unfortunately, as with GE2270 A, these novel
molecules are plagued by solubility and stability problems. In
2012, the same group reported the synthesis of a novel
derivative of thiomuracin A (18), termed NVP-LDU796 (19),
which retains antibacterial activity and shows improved
chemical stability and physiochemical properties
(Figure 14).[87] Key modifications include removal of the
C2–C10 side chain and conversion of the C84 epoxide into an
N70–C84 pyrrolidine ring. In co-crystal structures of NVP-
LDU796 (19) with EF-Tu, the conformation adopted is very
similar to the those of GE2270 A and LFF571, with key
interactions still present (PDB ID: 4G5G).[87]
2.4. Tetracyclines
Tetracyclines are broad-spectrum antibiotics with activity
against both Gram-positive and Gram-negative bacteria.[88]
Chlortetracycline (20), the oldest member of this class, was
discovered in 1945 and first used clinically in 1948
(Figure 16).[89] Since then, only three other naturally occur-
ring tetracyclines have been discovered (tetracycline (21),[90]
oxytetracycline (22)[91] and demethylchlortetracycline
(23)[92]), while countless others have been derived semi-
synthetically, including doxycycline (24)[93] and minocycline
(25).[94] Tetracyclines are easily recognizable by their four
highly oxygenated fused rings and they show favorable
antimicrobial properties along with an absence of major
side effects, which has led to their extensive use in both
human and animal infections. The third generation of
tetracyclines, the glycylcyclines (Figure 17), were introduced
10 years ago, with the first and so far only clinically used
member being tigecycline (26, previously GAR-936, discov-
ered at Wyeth-Ayerst Research).[95]
Glycylcyclines can be recognized by the glycylamido
substituent on the C9 carbon. The tert-butylglycylamido
moiety of tigecycline engages in stacking interactions with
C1054 of the 16S rRNA, which leads to increased potency of
tigecycline compared to tetracycline (Figure 18).[96]
Tetracyclines are primarily bacteriostatic. They penetrate
the outer membrane of Gram-negative bacteria by passive
diffusion through the OmpF and OmpC porin channels as
divalent metal-ion chelates.[88] Once inside the periplasm, the
liberated neutral tetracycline diffuses through the inner
Figure 15. Co-crystal structure of LFF571 (17; C green) and EF-Tu
(PDB ID: 3U2Q) from E. coli. The carboxylic acid groups of LFF571 are
in proximity to Arg223 and Arg262.
Figure 17. Structures of representative glycylcycline and aminomethyl-
cycline antibiotics.
Figure 16. Structures of representative tetracycline antibiotics.
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membrane in the same way that it penetrates Gram-positive
bacteria and other organisms, namely by energy-dependent
active transport. Once inside the cytoplasm, the higher pH
and metal-ion concentration lead to the regeneration of
a metal-ion/tetracycline complex that is postulated to be the
active species. This complex then binds reversibly to the
A site on the head of the 30S subunit (Figure 18).[96, 97] This
binding site has a slight overlap with the anticodon stem-loop,
which correlates well with previous observations that tetracy-
cline prevents binding of the aforementioned aa-tRNA·EF-
Tu·GTP ternary complex to the A site.[98]
Resistance to tetracyclines can occur through four differ-
ent mechanisms.[88] The proteins responsible for three of these
mechanisms are encoded by the tet (tetracycline) and otr
(oxytetracycline) genes, over 40 of which have been charac-
terized. Of these, only three, namely tet(X), tet(34), and
tet(37), lead to an enzymatic-alteration resistance mechanism
where the encoded proteins chemically modify tetracycline.[88]
Of the remaining genes, approximately two thirds encode
efflux proteins and the others encode ribosomal protection
proteins (RPPs). The efflux proteins occur in both Gram-
positive and Gram-negative bacteria, but are more prominent
in the latter. They are membrane-associated proteins and
export tetracyclines from the cell, which effectively protects
the ribosome by reducing the intracellular concentration of
the antibiotic. Ribosomal protection proteins are cytoplasmic
proteins that protect the ribosome from the action of
tetracyclines by reducing their susceptibility. They are also
found in both Gram-positive and Gram-negative bacteria, but
they are usually more common in Gram-positive organisms,
and tet(M) and tet(O) are the two most common genotypes.
Mechanistically, these proteins cause allosteric disruption of
the primary tetracycline binding site, which leads to the
release of bound tetracycline molecules.[99] The ribosome is
then able to return to its productive conformation and resume
protein synthesis. The last and most recent mechanism of
resistance involves mutations in the vicinity of the tetracycline
binding site.[100]
The presence of the tert-butylglycylamido moiety in
tigecycline (26) interferes with the binding of TetM to the
ribosome and thereby enables the drug to overcome TetM-
mediated resistance. As shown in Figure 19, tigecycline and
TetM overlap in the ribosome owing to the bulky tert-
butylglycylamido substitution of the drug molecule.[96]
2.4.1. Omadacycline
Omadacycline (27; previously PTK-0796, Paratek Phar-
maceuticals, Figure 17) is a semisynthetic tetracycline deriv-
ative and the first member of the novel aminomethylcycline
class. It is currently undergoing phase III clinical trials for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI), community-acquired bacterial pneumonia
(CABP), and complicated urinary tract infection (cUTI).
Omadacycline has been shown to be active against strains that
express either efflux proteins (tet(K)) or ribosome protection
(tet(M)), while also exhibiting moderate inhibition of pepti-
doglycan synthesis.[101,102] The exact mechanisms by which
omadacycline evades both efflux and ribosome protection are
not fully known, but it is believed that omadacycline is a poor
substrate for efflux transporters and that it binds in a unique
way that circumvents the action of ribosome protection
proteins.[101] Both of these factors almost certainly arise from
the structural modification at C9 of the tetracycline core.
2.5. Aminoglycosides
Aminoglycosides are hydrophilic molecules comprised of
a central aminocyclitol core linked to one or more amino
sugars. In most cases, the aminocyclitol is streptamine or 2-
deoxystreptamine (28 and 29, Figure 20). Depending on the
substitution pattern, aminoglycosides can be grouped into
four different subfamilies: monosubstituted (such as neamine
(30)),[103] atypical, 4,5-disubstituted, and 4,6-disubstituted
(Figure 20).[104] The aminoglycoside family of antibiotics is
one of the oldest, with its first member, streptomycin (31),
being discovered more than 70 years ago in 1944.[105] Despite
their long history, widespread resistance, and possible safety
issues such as nephrotoxicity and ototoxicity, aminoglycosides
are still widely used.[106]
Figure 18. Overlay of tetracycline (21; C yellow; PDB ID: 4V9A) and
tigecycline (26 ; C green, Mg2+ ions light brown; PDB ID: 4V9B) bound
to the 30S ribosomal subunit (PDB ID: 4V9B) from Thermus thermo-
philus. Tigecycline makes additional stacking interaction with C1054
compared to tetracycline. T. thermophilus numbering is used for the
nucleotides.
Figure 19. Overlay of TetM (blue ribbon; PDB ID: 3J25) and tigecycline
(26 ; C green, Mg2+ ions light brown; PDB ID: 4V9B) bound to the 30S
ribosomal subunit (PDB ID: 4V9B) from T. thermophilus. The super-
imposition was generated by means of the cryo-electron microscopy
density map EMD-2183 of the TetM-70S complex from E. coli according
to Jenner et al. and Dçnhçfer et al.[96, 99]
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The aminoglycosides have two distinct main mechanisms
of action. They are not only potent inhibitors of translocation
but are also able to induce misreading by stabilizing the
binding of near-cognate tRNAs and promoting their incor-
poration into peptide chains.[104] The high fidelity of trans-
lation (error frequencies ranging from 10¢3 to 10¢4 per
codon)[107] is achieved by the ability of the ribosome to
select the proper (cognate) tRNA over a wrong (non-
cognate) one at the A site.
The structure of the 30S ribosome shows a “decoding” site
within helix 44 (h44) of the 16S rRNA. In this asymmetric
internal loop, two universally conserved adenine residues,
A1492 and A1493, are directly involved in the decoding
process, during which they flip out of the helix to analyze the
codon–anticodon complex.[108] The energy needed for this flip
is thought to be compensated by stabilizing interactions
between the nucleotides and the codon–anticodon complex,
but only in the case of a cognate tRNA. When a non- or near-
cognate tRNA binds, the energy compensation is insufficient
and the tRNA dissociates. Upon binding within the internal
loop of h44, aminoglycosides induce a local rearrangement
that flips A1492 and A1493 out of the helix and stabilizes
them in this open conformation (Figure 21).[109] This results in
near-cognate tRNA being fully accommodated in the A site,
with the consequence that incorrect amino acids are incorpo-
rated into the peptide chain.
When the altered proteins are inserted into the cell
membrane, the permeability is modified, which in turn leads
to an increase in aminoglycoside uptake (hence their high
bactericidal and concentration-dependent activity). Co-crys-
tal structures of a variety of bound aminoglycosides have been
published, including with streptomycin (31, PDB ID:
1FJG),[110] spectinomycin (32, PDB ID: 1FJG),[110] hygro-
mycin B (33, PDB ID: 1HNZ),[97] neomycin B (34, PDB ID:
4V52),[111] paromomycin (35, PDB ID: 1FJG, 1IBK),[110,112]
tobramycin (36, PDB ID: 1LC4),[113] and kanamycin A (37,
PDB ID: 2ESI).[109]
Bacteria have developed three different mechanisms of
resistance to aminoglycosides: uptake inhibition or efflux,
ribosome modification, and aminoglycoside modification.[114]
The first two mechanisms are relatively rare and have not
been targeted yet. Aminoglycoside-modifying enzymes
(AMEs), on the other hand, are widespread and the most
common mechanism of resistance. These enzymes are de-
scribed according to the modification they promote, along
with the carbon atom at which the modification takes
place.[115] The three known types of enzymes are aminoglyco-
side N-acetyltransferases (AACs), aminoglycoside O-nucleo-
tidyltransferases (ANTs), and aminoglycoside O-phospho-
transferases (APHs). Figure 22 shows the co-crystal structure
of kanamycin A (37, Figure 20) with the aminoglycoside-
modifying enzyme ANT(2’’)-Ia.[116] The 2’’ hydroxy group is
complexed to the magnesium ion, ready to be modified by the
enzyme.
A second generation of aminoglycosides called neoglyco-
sides,[117] which maintain the potency of first-generation
aminoglycosides while evading modification enzymes, is
currently being researched.
2.5.1. Plazomicin
Two aminoglycosides, sisomicin[118] and amikacin[119] (38
and 39 ; Figure 23), were used as inspiration for the develop-
ment of the semisynthetic plazomicin (40, formerly ACHN-
Figure 20. Structures of typical and atypical aminoglycosides. The
aminocyclitol core is highlighted in blue.
Figure 21. Kanamycin A (37; C green) in complex with a decoding A-
site oligonucleotide (PDB ID: 2ESI). A1492 and A1493 are kept in the
flipped-out position by kanamycin A. E. coli numbering is used for the
nucleotides.
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490, developed by Achaogen), which is the first molecule of
this new family (Figure 24).[117]
The difference between sisomicin and plazomicin is the
presence of two side chains on the nitrogen atoms at C1 and
C6’ in plazomicin. As highlighted in Figure 24, the hydrox-
yethyl chain shown in red blocks AAC(6’), while the
amikacin-derived hydroxyaminobutyric acid (HABA) chain
shown in blue blocks AAC(3) along with ANT(2’’) and
APH(2’’).[120,121] Compared to kanamycin A, plazomicin is
also protected from APH(3’) and ANT(4’) by the absence of
hydroxy groups at positions C3’ and C4’. The only amino-
glycoside-modifying enzymes that plazomicin is still vulner-
able to are AAC(2’) enzymes, but so far the expression of
these enzymes has been detected only in Providencia stuartii.
In MDR Enterobacteriaceae, including carbapenem-resistant
Enterobacteriaceae (CRE), plazomicin remains active where
most other antibiotics, including the commercially available
aminoglycosides, show limited potency owing to resistance.
3. Cell Wall Synthesis Inhibitors
The bacterial cell wall is made of peptidoglycan, itself
composed of strands of glycan units linked by peptides. Its
synthesis takes place in three steps, starting in the cytoplasm,
passing through the inner-membrane, and ending in the
periplasm (Figure 25). The mechanism of this synthesis has
been thoroughly studied and will only be briefly discussed
here.[122] The initial precursor, UDP-MurNAc, is generated
from UDP-GlcNAc by the action of the transferase MurA
and the reductase MurB. To this glycan, five amino acids are
then attached sequentially by the ligases MurC–MurF. The
last two d-Ala residues are generated from l-Ala by the
alanine racemase Alr and linked to the chain by the alanine
ligase Ddl. The MurNAc pentapeptide is then transferred to
an undecaprenyl pyrophosphate by the translocase MraY,
followed by the addition of a GlcNAc unit by the glycosyl-
transferase MurG to give Lipid II. Finally five l-Gly units are
attached to Lipid II by the acyltransferases FemX, FemA, and
FemB. Lipid II is then transferred from the cytoplasm to the
periplasm through the inner membrane by flippases such as
FtsW and RodA. Once in the periplasm, Lipid II is incorpo-
rated into the peptidoglycan cell wall by the action of two
successive penicillin-binding proteins (PBPs). The first,
a transglycosylase, catalyzes polymerization of the glycan
strands, while the second, a transpeptidase, crosslinks the
glycan strands into a three dimensional mesh.
A large number of antibiotics target the synthesis of
peptidoglycan or its precursors, which results in cell death
(Figure 25). Eukaryotic cells do not possess a peptidoglycan
cell wall, which makes these antibacterial agents selective for
bacteria.
3.1. Glycopeptides and Lipoglycopeptides
Vancomycin (41, Figure 26), the prototypical glycopep-
tide, was isolated in the 1950s from microbes found in soil
samples (Eli Lilly and Company)[123] and its structure was
determined in the early 1980s.[124] It is a hydrophilic rigid
glycopeptide with poor absorption in the gastrointestinal (GI)
tract. It was first used in the clinic in 1959, but owing to its
toxicity, it was usually only used as a last resort. While
resistance was slow to develop, high-level resistance was
reported in 1986 in enterococci.[124]
Glycopeptides all share a common mode of action, which
consists of binding to the C-terminal d-alanyl-d-alanine of
peptidoglycan precursors.[125] This was first discovered in
vancomycin in the late 1960s and then confirmed by NMR
studies by theWilliams group in 1983.[126]More recently, these
results have been confirmed by X-ray crystallography.[127–129]
Figure 22. Co-crystal structure of kanamycin A (37; C green) and
adenylyltransferase ANT(2“)-Ia (Mg2+ ions light brown; PDB ID:
4WQL) from Klebsiella pneumoniae. Kanamycin A is kept in place by
a hydrogen-bonding network.
Figure 23. Structures of sisomicin and amikacin.
Figure 24. Structure of plazomicin and AME modification sites. The
HABA chain (blue) blocks modifications at the 3-N and 2’’-O positions,
the hydroxyethyl chain (red) blocks modifications at the 6’-N position,
and the absence of hydroxy groups at C3’ and C4’ prevents modifica-
tion at these positions. Only the 2’-N position remains unblocked to
AACs.
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The resulting steric hindrance from this binding inhibits the
transglycosylation and transpeptidation steps in cell wall
synthesis ultimately resulting in bacterial cell death
(Figure 26).[125]
To circumvent glycopeptides such as vancomycin, bacteria
have developed numerous mechanisms of resistance, the most
common phenotype being VanA.[130] This phenotype shows
substitution of the d-Ala-d-Ala terminus on peptidoglycan
residues by d-Ala-d-Lac. Vancomycin can therefore only
form four of the usual five hydrogen bonds with the resulting
depsipeptide, the last one being replaced by a destabilizing
lone-pair/lone-pair interaction.[130] This seemingly small
change results in reduction of the binding affinity between
the antibacterial agent and the target by up to 1000 fold.[130]
3.1.1. Vancomycin Analogues
The Boger group at Scripps has carried out a tremendous
amount of work on the synthesis of vancomycin and its
analogues, focusing on binding to d-Ala-d-Lac strands.[131] In
resistant bacteria, peptidoglycans with the d-Ala-d-Lac
terminus only make four hydrogen bonds with vancomycin,
resulting in a 1000-fold loss in binding affinity. This figure can
be divided into two factors: a 10-fold decrease as a result of
the loss of a hydrogen bond, and a 100-fold decrease owing to
repulsion of the lone pairs on the two nearby oxygen
atoms.[132] In order to try and regain the lost binding affinity,
a series of vancomycin analogues was synthesized with
modifications at the carbonyl group of residue 4 (Fig-
ure 27A).[131,133]
The thioamide equivalent proved to be completely
inactive against both vancomycin-sensitive and vancomycin-
resistant bacteria. This was postulated to be due to the
increased bond length and size of the sulfur atom, which
presumably prevents binding of the ligand. The reduced
analogue, in which the carbonyl is replaced by a methylene
group, did not reinstate the lost hydrogen bond but did
remove the predominant lone-pair repulsion factor. This led
to an increase in binding affinity for the mutated d-Ala-d-Lac
strand. The best results were obtained when the amide was
replaced by an amidine. Indeed, as seen in Figure 27B, the
amidine can serve a dual role. In the case of binding to d-Ala-
d-Ala strands, the nitrogen atom can take the role of
a hydrogen-bond acceptor, whereas in the case of binding to
d-Ala-d-Lac strands, it can serve as a hydrogen-bond donor.
This, in combination with the introduction of a lipophilic 4-(4-
chlorophenyl)benzyl side chain derived from oritavancin[134]
(which allows the antibiotic to anchor into the bacterial cell
Figure 25. Cell wall synthesis. Antibacterial targets are highlighted.
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membrane, thus bringing target and host closer together),
resulted in impressive antibiotic activities against both
vancomycin-sensitive and vancomycin-resistant bacteria
(MIC= 0.06–0.005 and 0.5–
0.06 mgmL¢1 for the amidine and
methylene analogues, respec-
tively).[133]
3.2. b-Lactams
In 1928, Alexander Fleming
discovered the inhibitory effect of
a Penicilliummold on the growth of
bacteria.[135] Nevertheless, it wasnÏt
until 1941 that penicillin was used
for the first time to treat human
patients.[136] To this day, b-lactam
antibiotics are still widely used
around the globe, and medicinal
chemists have developed numerous
variations and generations of this
scaffold.[137] The mechanism of
action of b-lactams involves cova-
lent binding to transpeptidases,
thereby inhibiting cell wall synthe-
sis.[138] Indeed, b-lactams mimic the
d-Ala-d-Ala terminal sequence of
peptidoglycan chains, the natural
substrate of transpeptidases
(Figure 28, top right).
As seen in Figure 28, the distance between the two
carbonyls of the peptidoglycan chain is very similar to the
distance between the carboxylic acid and the b-lactam
carbonyl. The antibiotic therefore acts as a competitive
antagonist for the transpeptidase enzyme. Mechanistically,
the hydroxy group of a serine residue reacts with the lactam
carbonyl, which leads to opening of the four-membered ring
(Figure 28, purple cycle).[136] The resulting acyl enzyme
(Figure 29) is stable, and hydrolysis is very slow (low k3),
Figure 27. A) Modifications made by the Boger group to vancomycin.
Addition of the lipophilic side chain from oritavancin is shown in
green; modifications to the carbonyl of residue 4 are shown in purple.
B) Dual binding behavior of the amidine functional group.
Figure 26. Diagram of the binding of vancomycin to Lipid II sterically prevents the transglycosylation
and transpeptidation steps. Key interactions of vancomycin with the d-Ala-d-Ala fragment shown in
blue and were identified from co-crystal structures of vancomycin with analogues of cell-wall
precursors (PDB ID: 1FVM).[129]
Figure 28. The structural similarities between the core of b-lactam
antibiotics and the d-Ala-d-Ala terminal sequence of peptidoglycan
chains (blue), and the general mechanism of action of transpeptidases
(purple) and b-lactamases (orange).
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thus rendering the enzyme inactive and ultimately leading to
cell lysis and death.[139]
Resistance to b-lactams occurs through four mecha-
nisms.[140] The first two are relatively rare and only occur in
Gram-negative bacteria. One involves alteration of the porin
channels, which prevents access to the transpeptidases, while
the other involves efflux pumps that export the antibiotic.
These mechanisms have not been specifically targeted in
recent antibiotics. The third and most common mechanism of
resistance is the production of b-lactam-hydrolyzing enzymes.
These enzymes are structurally very similar to the trans-
peptidase enzymes and mechanistically function in a similar
manner by opening the b-lactam ring (Figure 28, orange
cycle).[140] What differentiates the two is the fact that while
acyl transpeptidases were slow to hydrolyze, the acylated b-
lactamases are hydrolyzed at a much faster rate (high k3). This
rapid hydrolysis results in regeneration of the b-lactamase
and inactivation of the antibiotic. Originally, b-lactams were
synthetically modified to resist and evade b-lactamases, which
led to so many scaffolds and multiple generations of these
types of antibiotics. The focus has nowadays shifted to the use
of b-lactamase inhibitors co-administered with b-lactams (see
Section 4).
The fourth mechanism of resistance, which is present in
MRSA, is the presence of an exogenous b-lactam-resistant
PBP called PBP2a. Studies on this PBP and the similar PBP2
have provided details on the resistance mediated by
PBP2a.[141,142] The binding pocket for the antibiotic in
PBP2a exists in an unreactive conformation since the active
serine (Ser403) is misaligned and acylation does not take
place. It was postulated that only under acidic conditions or if
the b-lactam possesses a bulky hydrophobic substituent,
would acylation take place.[143] Indeed, allosteric interactions
are required to trigger a conformational change that opens
the active site. Following these findings, three so-called “fifth-
generation” cephalosporins, namely ceftaroline,[144] ceftobi-
prole,[145] and ceftolozane,[146]were developed by following the
currently known SAR (Figure 30), and these show activity
against MRSA.
3.2.1. Ceftaroline
Ceftaroline fosamil (42 ; previously PPI-0903, TAK-599,
Forest Laboratories) is the prodrug of ceftaroline (43),
a novel broad-spectrum cephalosporin approved by the
FDA in 2010 (Figure 31). Like other b-lactams, it shows
bactericidal activity against Gram-positive organisms but also
against MRSA.
Ceftaroline was developed by modifying cefozopran (44),
a fourth-generation cephalosporin. As seen in Figure 31, the
western half remains mostly unchanged, with the 1,2,4-
thiadiazole and oxime moieties still present for Gram-
negative penetration and b-lactamase resistance, respec-
tively.[144] Once bound, ceftaroline has been shown to undergo
hydrolysis at a very slow rate.[144] The phosphono group in the
prodrug ceftaroline fosamil is used to increase water solubility
Figure 29. X-ray structure of penicillin G (C green) covalently bound
via Ser62 to penicillin-binding protein 4 of E. coli (PDB ID: 2EX8).
Figure 30. Summary of cephalosporin structure–activity and structure-
property relationships.
Figure 31. Structures of cephalosporins.
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and is rapidly cleaved in the plasma to deliver the active drug
ceftaroline.[147] For ceftaroline, an allosteric binding site at
PBP2a has been identified by crystallographic analysis
(Figure 32). The allosteric binding site (Figure 32C) is
separated from the active site (Figure 32B) by a remarkable
60 è distance (Figure 32A).[148] Crystallographic analysis also
revealed the identity of other allosteric ligands for PBP2, such
as muramic acid (a saccharide component of the peptidogly-
can). Therefore, it has been proposed that the function of the
allosteric domain is to sense nascent peptidoglycan and then
open the active site to catalyze the transpeptidation.[148] The
elucidation of the ability of the anti-MRSA b-lactam anti-
biotic ceftaroline and other molecules to trigger allosteric
opening of the active site so that PBP2a can be inactivated by
a second b-lactam molecule, should enable future structure-
based design campaigns for b-lactam antibiotics.
After the introduction of ceftaroline to the clinic, clinical
strains resistant to this antibiotic were reported. Two sets of
mutations within the PBP2a sequence were described (the
double mutant N146K/E150K and the triple mutant N146K/
E150K/H351N).[149] These mutations are distant from the
active site of PBP2a, hence their functions cannot be under-
stood by a loss of affinity of the antibiotic for the active site of
the target protein. Interestingly, the N146K and E150K
mutations are both within the allosteric domain of PBP2a,
whereas the H351N mutation is outside of both the allosteric
and active sites. By kinetic studies and by X-ray crystallog-
raphy of the mutants, Mobashery, Hermoso et al. were able to
rationalize that the clinically observed mutations interfere
with triggering of the allosteric signal by ceftaroline along the
interacting amino acid network between the two sites.[148,150]
These mutations allow the mutant variants of PBP2a to
manifest resistance to ceftaroline by two different mecha-
nisms: the first is a modest increase in the dissociation
constant for ceftaroline binding to the
allosteric site, and the second is disrup-
tion of the transmission of conforma-
tional changes necessary for opening the
active site. This results in resistance to
ceftaroline by an unprecedented mecha-
nism, namely interference with the fidel-
ity of the allosteric response.[150]
3.2.2. Ceftolozane
Ceftolozane (45 ; previously CXA-101
and FR264205, discovered at Astellas
Pharma, developed by Cubist Pharma-
ceuticals) is the b-lactam component of
the cephalosporin/b-lactamase inhibitor
combination Zerbaxa, which was
approved by the FDA in December
2014.[151]
As shown in Figure 31, ceftolozane is
derived from the third-generation cepha-
losporin ceftazidime (46). It maintains
the aminothiadiazole ring and oxime
functional groups of ceftaroline and cef-
tobiprole, which confer enhanced activity
against Gram-negative bacilli and stabil-
ity against b-lactamases, respectively.[151]
Additionally the appended dimethylace-
tic acid moiety provides improved anti-
pseudomonal activity.[146,151] On the east-
ern side, a highly substituted pyrazole
ring provides the steric bulk necessary to reduce hydrolysis by
b-lactamases.[151] The SAR of the substitution pattern of the
pyrazole ring was studied in detail, and a 5-amino-1-methyl-
1H-pyrazol-2-ium moiety was found to confer the highest
antipseudomonal activity.[146] Additionally, the basicity of the
substituent at the 3-position of the cephalosporin nucleus
could be correlated with improved outer membrane perme-
ability. Unfortunately, this also led to increased convulsion
induction in mice. The solution was found by introducing
basic side chains at position 4 of the 5-amino-1-methyl-1H-
pyrazol-2-ium, with the 2-aminoethylureido group eventually
found to have the best balance.
Ceftolozane shows broad-spectrum activity, including
against drug- and multidrug-resistant Pseudomonas aerugi-
nosa, along with potent antipseudomonal activity.[151, 152]
Unfortunately, like other oxyimino cephalosporins, it is
sensitive to extended-spectrum b-lactamases (ESBL) and
carbapenemases. For this reason, ceftolozane is marketed in
conjunction with the b-lactamase inhibitor tazobactam (see
Section 4), which broadens its spectrum to include ESBL-
producing strains of P. aeruginosa and Bacteroides fragi-
lis.[151, 153]
Figure 32. A) An overview of the two binding sites of ceftaroline (43 ; C green [allosteric site]
and orange [active site]) in PBP2a from S. aureus (PDB ID: 3ZG0). B) Ceftaroline (43 ; C
orange) covalently bound within the active site of PBP2a (gray ribbon, PDB ID: 3ZG0). Once
ceftaroline is bound to the allosteric site, the active site opens up in comparison to the closed
state (blue ribbon, PDB ID: 4BL2). C) Ceftaroline (43 ; C green) bound non-covalently to the
allosteric binding site of PBP2a (PDB ID: 3ZFZ).
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3.2.3. BAL30072
Siderophores are small molecules that chelate iron ions,
and they allow bacteria to acquire this essential element from
the environment for vital cellular processes.[154]
The siderophore-containing b-lactam BAL30072 (47;
Figure 33, developed by Basilea Pharmaceutica AG)[155] is
a siderophore sulfactam conjugate derived from tigemonam
(48) with an additional dihydroxypyridinone moiety to
chelate iron.[156] It serves as a bioisostere for catechol, and
the BAL30072-Fe3+ complex can thus be actively transported
through the outer membrane.[157] Inside the bacteria, it
inhibits PBP1a, PBP2a, and PBP3 and acts as an inhibitor
of class C b-lactamases.[155] BAL30072 shows good antibacte-
rial activity in vitro against Gram-negative bacteria, is active
in vivo against Acinetobacter baumannii, and features syner-
gistic activity in combination with carbapenems.[155,158,159]
In 2014, Starr et al. reported PBP3/BAL30072 co-crystal
structures, which showed that the siderophore moiety might
not be at the ideal position. Indeed, compared to aztreonam
(49 ; Figures 33 and 34A),[160] another similar monobactam,
the molecule misses some favorable interactions, such as a salt
bridge with Arg489 and a hydrophobic pocket interaction
with the gem-dimethyl group of the antibiotic (Fig-
ure 34B).[161] Based on these structure-based findings, medic-
inal chemists tried to install the siderophore moiety at a more
beneficial position.[161–163] Compound 50 (Figure 33, discov-
ered at AstraZeneca) represents a most recent successful
example of such a structure-based approach that allows the
design of siderophore-conjugated monocarbams with opti-
mized binding interactions to P. aeruginosa PBP3 (Fig-
ure 34C).[163] Besides reinstalling the strong interaction of
the drug molecule with Arg489, it positions the polar side-
rophore in a more hydrophilic environment and allows the
drug to make additional interactions with the target protein
PBP3 (Figure 34C). Compound 50 features excellent phar-
macokinetic properties and strong cellular activity against P.
aeruginosa (P. aeruginosa ARC545; MIC= 0.5 mgmL¢1).[163]
Figure 33. Monocyclic b-lactams with the siderophores highlighted in
blue.
Figure 34. Comparison of siderophore-conjugated monocyclic b-lactam
antibiotics. A) Aztreonam (49 ; C light blue) covalently bound to PBP3
(PDB ID: 3PBS) from P. aeruginosa. The carboxylic acid moiety (C
green) of aztreonam engages in polar interactions with Arg489, and
the gem-dimethyl group interacts with the hydrophobic pocket formed
by Tyr503, Tyr532, and Phe533. B) X-ray structure of BAL30072 (47; C
light blue) covalently bound to PBP3 (PDB ID: 4OOM) from P.
aeruginosa. The siderophore moiety (C purple) of BAL30072 replaces
the carboxylic acid and forces Arg489 into a non-binding orientation.
C) The crystal structure of 50 (C light blue) covalently bound to PBP3
(PDB ID: 4WEL) from P. aeruginosa demonstrates optimized binding
of the siderophore monocarbam conjugate (siderophore moiety: C
purple; carboxylic acid moiety: C green).
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4. b-Lactamase Inhibitors
As discussed previously, b-lactam antibiotics are one of
the oldest and most used classes of antibiotics. Resistance to
these antibacterial agents predominantly occurs through the
production of two different types of molecules: b-lactamases
and b-lactam-resistant PBPs. b-Lactamases have been classi-
fied according to two schemes: the Ambler and the Bush–
Jacoby classification.[164,165]
The first b-lactamase inhibitor to be used was clavulanic
acid (51, discovered at Beecham Pharmaceuticals) in the mid-
1970s,[166] followed over the next decade by sulbactam (52)[167]
and tazobactam (53).[168] As seen in Figure 35, these b-
lactamase inhibitors all possess a b-lactam core, but they have
been shown to have only limited antibiotic activity. Their
mode of action involves irreversible binding to b-lactamases,
which prevents inactivation of the antibiotic (Figure 36).[169]
Unfortunately these three b-lactamase inhibitors are only
effective against one of the four classes of b-lactamases, and
the number of naturally occurring b-lactamases has risen
exponentially over the last 20 years since the introduction of
tazobactam. Novel b-lactamase inhibitors with extended
spectra are now greatly needed. New b-lactamase inhibitors
that are based on structural design and do not contain a b-
lactam structure are currently being investigated.
4.1. Diazabicyclooctanes
The first class of these “non-b-lactam inhibitors” are the
diazabicyclooctanes (DBOs), which were first proposed in the
mid-1990s (Hoechst Marion Roussel).[170,171] These inhibitors
are more potent and have a broader spectrum than current b-
lactamase inhibitors. Mechanistically, they act in a similar
manner to the traditional b-lactam inhibitors, with the
carbonyl group of the cyclic 5-membered urea (imidazoli-
din-2-one) serving as the electrophile for the active-site serine
of the b-lactamase. This structural similarity to b-lactams is
highly important for rapid recognition by the b-lactamase
(Figure 37). Unlike the traditional b-lactam inhibitors how-
ever, they are not subject to hydrolysis after acylation, but
instead deacylate very slowly. Two of these novel DBOs will
be discussed here.
4.1.1. Avibactam
Avibactam (54 ; previously NXL-104, AVE1330A, devel-
oped by Actavis) is a DBO that was approved by the FDA in
2015 in combination with the b-lactam ceftazidime (46) and is
still in clinical studies in combination with ceftaroline (43) and
aztreonam (49).[172] It is a covalent, reversible inhibitor that
has been shown to have a very fast “on” rate, as well as a very
slow “off” rate for deacylation, with a half-life measured in
days.[173]X-ray crystal structures of avibactam in complex with
three different b-lactamases have provided important insight
into the mode of action.[174–176] Avibactam interacts with
conserved key residues in a fairly rigid conformation, and the
highly polar sulfate group (which mimics the b-lactam
carboxylic acid, Figure 37) engages in strong polar interac-
tions with Arg261 (Figure 38).[177] Once covalently bound,
avibactam remains in a similar conformation, which, along
with the stability of the newly formed carbamoyl bond and the
additional favorable interactions, explains the deacylation
pathway over hydrolysis. Given the small size of avibactam
and the efficient interactions with key catalytic residues near
the active site, this should allow binding to nearly all b-
lactamases. This could have positive implications for the
suppression of emergence of new resistance in the clinic.
4.1.2. Relebactam
Relebactam (55 ; previously MK-7655, Merck and Com-
pany, Figure 37) is structurally very similar to avibactam, the
only difference being the addition of a piperidine ring on the
Figure 35. The three b-lactamase inhibitors with b-lactam cores that
are currently in clinical use.
Figure 36. Crystal structure of tazobactam (53 ; C green) covalently
bound via Ser70 to the b-lactamase SHV-1 (PDB ID: 2H10) from K.
pneumoniae.
Figure 37. The diazabicyclooctane (DBO) non-b-lactam inhibitors and
similarity with the b-lactam core (blue).
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amide. The choice of this heterocycle came from screening
a variety of basic and neutral heterocyclic side chains, taking
into account results obtained with a previous inhibitor MK-
8712 (56).[178] It was found that the addition of a basic nitrogen
atom greatly helped to reduce efflux from the bacterial
cell.[178]
4.2. Boronic Acids
Boronic acids were already recognized as effective
inhibitors of serine proteases in the 1970s.[179] Indeed, the
boron atom can act as an electrophile, mimicking a carbonyl
carbon atom, which can lead to the formation of a reversible
covalent bond between the serine and the boronate moiety.
Since Kiener and Waley described the use of phenylboronic
acid as a b-lactamase inhibitor in 1978, a number of research
groups have looked into this functional group to generate
novel inhibitors.[180] Surprisingly, it is only very recently that
the first boronate has been tested in an animal infection
model.[181]
4.2.1. RPX7009
A cyclic boronic acid b-lactamase inhibitor is currently
under development (Rempex Pharmaceuticals, a subsidiary
of The Medicines Company). The original inspiration for its
design comes from a report published in 2000 by Ness and co-
workers in which compound 57 is described.[182] This led to the
idea of using cyclic boronates as inhibitors. With the boronic
ester locked in a ring, the inhibitor is constrained into
a preferred conformation, thereby resulting in increased
potency. Computational docking of several structures with
different b-lactamase enzymes led to the discovery of the core
structure shown in Figure 39. From this first hit, a large
variety of compounds with varying N-acyl substituents were
synthesized. The 2-thienyl acetyl analogue RPX7009 (58) was
found to be the most potent derivative, while also displaying
a broad spectrum of inhibition and high selectivity.[181]
RPX7009 is a broad-spectrum inhibitor, notably restoring
the activity of carbapenems against carbapenemase-produc-
ing K. pneumoniae strains. Combined with a carbapenem,
RPX7009 is a promising candidate for the treatment of
multidrug resistant Gram-negative bacteria.[183]
X-ray co-crystal structures of RPX7009 with b-lactamase
enzymes confirmed the boron atom as the electrophilic site
for the serine addition, as well as a hydrogen-bonding
network between both the amide and the carboxylic acid
groups and the enzyme backbone (Figure 40). This informa-
tion could be used for further structure-based optimization of
this novel chemotype of b-lactamase inhibitors.
4.2.2. Oxaboroles
Recently, the design and synthesis of broad-spectrum
boron-based b-lactamase inhibitors has been published
(AstraZeneca).[184] The approach taken is a very nice and
well described example of structure-based drug design that
could potentially inspire future work in this field.
Verheijen et al. used two recent publications as starting
points to come up with 2-(1-hydroxy-6-phenoxy-1,3-
dihydrobenzo[c][1,2]oxaborol-3-yl)acetic acid (59) as an ini-
tial scaffold (Figure 41).[185, 186] An SAR study revealed the
importance of the carboxylic acid and ether substituents.
While the phenyloxy-substituted analogue showed slightly
higher affinity against a panel of representative b-lactamases,
the pyrazine analogues were synthetically less challenging
and were therefore preferred for further optimization studies.
Docking studies against various b-lactamases revealed
a lipophilic pocket near C4 and C5. This pocket was found to
Figure 38. X-ray structure of avibactam (54 ; C green) bound via Ser81
to the b-lactamase OXA-24 (PDB ID: 4WM9) from A. baumannii.
Figure 39. Inspiration for and structure of RPX7009.
Figure 40. X-ray structure of RPX7009 (58 ; C green, B light magenta)
bound to AmpC (PDB ID: 4XUX) from Enterobacter cloacae.
Angewandte
ChemieReviews
6620 www.angewandte.org Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2016, 55, 6600 – 6626
be only able to accommodate small methyl groups, which led
to the advancement of compound 60. At this stage, chiral
separation also revealed that the R-enantiomer was the most
active. Finally the pyrazine ring was replaced with a number
of different heterocycles to try and increase the affinity for
class A, C, and D b-lactamases. Eventually, compound 61 was
found to have the highest overall affinity against various b-
lactamases, with half maximal inhibitory concentration (IC50)
values in the nanomolar range. For ceftazidime (46), the
application of 61 reduced the MIC in E. coli to 0.25 mgmL¢1.
The predicted binding model was also confirmed by X-ray
crystallography of 61 in co-crystal structures with different b-
lactamases (PDB IDs: 4WZ4 [with AmpC] and 4WZ5 [with
OXA-10]). Unfortunately, compound 61 produced only
modest restoration of susceptibility to ceftazidime in
a number of other Gram-negative pathogens such as P.
aeruginosa and A. baumannii.
5. Intervention at the Genetic Level
Transcription factors are responsible for the regulation of
gene transcription and are therefore essential in a wide
variety of cellular processes.[187] They contain specific DNA-
binding domains with which they bind to specific DNA
sequences and thereby regulate gene transcription. Interfer-
ence at the genetic level by using small molecules that target
the transcription factor binding sites enables control of gene
expression.[188,189] Since the ability of bacteria to develop
antibiotic resistance is encoded in their genomes, targeting
the relevant transcription factors offers a complementary
approach to fighting antibiotic resistance, in addition to the
development of new antibiotic compounds. This strategy
benefits from recent genomic data as well as from detailed
information about the molecular structure of transcription
factors.
Several promising results were recently achieved by using
either oligonucleotides (McArthur et al. , Procarta Biosys-
tems Ltd.)[190] or small drug-like compounds (Baulard et al.,
BioVersys AG, Riedl et al.)[191,192] as interfering molecules.
5.1. Targeting the Transcription Factor EthR
Baulard et al. delivered an excellent example of how to
target a transcription factor by structure-based design in order
to positively influence the genetic machinery of a bacterium
with respect to its susceptibility against a given antibiotic
agent.[191] They targeted the transcriptional repressor EthR,
a member of the TetR family of repressors,[193] which blocks
the transcription of ethA. This gene encodes the monoox-
ygenase EthA, which catalyzes the activation of the prodrug
ethionamide in Mycobacterium tuberculosis (Mtb).[194]
Ethionamide is recommended by the WHO for the
treatment of multidrug-resistant tuberculosis (MDR-TB),
but it has a low therapeutic index. Since most of the adverse
effects are dose-related, an increase in the bioactivation of
ethionamide should reinforce its benefit for the treatment of
MDR-TB. The analysis of X-ray data for EthR bound to
small-molecule ligands (PDB IDs: 1U9N, 1T56)[195,196] sug-
gested that holoprotein conformations are not able to bind
DNA. Selective binders to EthR would therefore inhibit the
repression of ethA expression. This should in turn boost the
activation of ethionamide and thus reduce the amount of
prodrug which needs to be administered. The chemical
structure and binding orientation of the initial ligands
identified in the co-crystal structures (PDB IDs: 1U9N,
1T56; Figure 42) inspired the fragment-based design and
synthesis of a focused library of drug-like small molecules.
Out of this library, they could identify the initial leads
BDM14500 and BDM31343 (62 and 63 ; Figure 43). These
compounds inhibit the DNA-binding function of EthR.
Further medicinal chemistry optimization by a structure-
based strategy led to compound 64 (Figure 43), which
decreases the Mtb load of infected mice three times more
effectively than ethionamide alone.[197] These boosters of
ethionamide bioactivation are currently being developed
toward preclinical testing.[198]
Figure 41. Structure–activity relationships contributing to the develop-
ment of new boron-based b-lactamase inhibitors (60, 61).
Figure 42. Overlay of the EthR crystal structure containing dioxane
fragments (C purple; PDB ID: 1T56) and the co-crystal structure of
BDM14500 (62 ; C green) bound to the transcription factor EthR
(PDB ID: 3G1O), both from M. tuberculosis.
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5.2. Targeting the Transcription Factor TetR
The transcription factor TetR has been successfully
targeted with drug-like small molecules in order to treat
tetracycline resistant Gram-positive and Gram-negative
pathogens (Bioversys AG in collaboration with our group).
These molecules, called transcription regulator inhibitory
compounds (TRICs) target transcription factors that are
responsible for the development of resistance.[192] The aim is
to use TRICs as adjuvants for restoring or potentiating the
impact of antibiotics in order to overcome bacterial resist-
ance.[198] Bacteria have developed extensive resistance mech-
anisms against tetracyclines, including tetracycline efflux,
ribosomal protection, and tetracycline modification.[199] The
two most dominant mechanisms in clinical settings are
ribosomal protection and efflux.[199] The latter is mediated
by the membrane transport protein TetA.[200] The expression
of this protein is regulated by the Tet repressor (TetR), which
binds to the DNA and prevents the transcription of tetA.[201]
When tetracycline binds to TetR with the aid of Mg2+
(Figure 44), such as when it binds to its ribosomal target,
the conformation of TetR changes and transcription of the
resistance genes take place.[199,201,202]
By following a structure-based approach based on the co-
crystal structure of TetR with tetracycline in combination with
a DNA/Protein (tetO/TetR) interaction assay, it was possible
to design and develop compounds ZHAWOC1035 and
ZHAWOC1132 (65 and 66 ; Figure 45), which specifically
bind to TetR and prevent its release from the DNA in the
presence of tetracycline.[192] In combination with tetracycline,
these drug-like small molecules were able to inhibit the
growth of tetracycline-resistant staphylococcal, enterococcal,
enterobacterial, and acinetobacter isolates.[192]
6. Summary and Outlook
The alarming spread of antibiotic resistance has been
recognized by relevant institutions such as the World Health
Organization. After decades of declining efforts by the
pharmaceutical industry in their search and development of
new antibiotic treatment options, the latest wake-up calls
have already brought some increase in activity in this exciting
area of multidisciplinary research. Structural and mechanistic
understanding of antibacterial targets and deciphering of the
bacterial ability for developing antibiotic resistance provide
a sound basis for rational campaigns against antibiotic
resistance. Screening for new natural or synthetic compounds
with antibiotic effects based on novel antibacterial targets still
provide one route to outstanding discoveries in the field[203]
but structural knowledge enables us to work directly on the
resistance mechanisms with increasing success, as shown by
some selected examples in this review. A multipronged
strategy that involves targeting traditional and emerging
antibiotic targets as well as pursuing adjuvant strategies at the
genetic level with non-antibiotic compounds for potentiating
known antibiotics gives rise to many opportunities to over-
come antibiotic resistance. Beyond the basic considerations of
the pharmaceutical industry concerning return on invest-
ments for the discovery and marketing of new antibiotic
treatments, there is the invaluable power of antibiotics, which
has helped to save a myriad of lives in the past and which
nobody would like to see disappear. Since the level of
resources required and the associated costs for developing
a new drug molecule are very high and the expected financial
gains from antibiotic treatments, which are typically only
required for short periods, are relatively low compared to
treatments for chronic conditions, the willingness for indus-
trial players to start substantial efforts to discover new
antibiotic treatment options remains low. Nevertheless,
pharmaceutical companies are needed as strong partners in
drug development programs, given their experience and
knowledge of the highly complex endeavor of bringing
a new drug molecule to the clinic. It is not sufficient to have
a compound that kills bacteria on a petri dish. It takes a lot of
complex medicinal chemistry optimization in order to be able
to use the compound to treat bacterial infections in humans.
Whereas the strength and mandate of academic institutions is
Figure 44. Co-crystal structure of tetracycline (21; C green, Mg2+ ion
light brown) bound to the transcription factor TetR (PDB ID: 2TRT)
from E. coli.
Figure 45. Transcription-factor-binding molecules for restoring tetracy-
cline susceptibility.
Figure 43. Boosters of ethionamide bioactivation.
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to develop novel strategies for ensuring antibiotic treatment
options for the future, the final processing of new antibiotic
drug molecules and their development through clinical
studies is the domain of the pharmaceutical industry. A
reasonable approach for integrating these two aspects is
a closer interaction between industrial and academic partners
in drug discovery for the mutual benefit of both partners and
the patients. There are several examples in which major
pharmaceutical companies have “opened their doors” and
started cooperating very early on with academic groups on
drug discovery projects. These “open innovation” collabora-
tions provide easy reciprocal access to resources that the
partners would not have otherwise. One characteristic of
those open innovation approaches is that they are not focused
on a specific drug development program from the beginning
but rather screen the best scientific ideas and strategies for
new therapeutic indications, including antibiotic resistance.
More focused collaborations can then be defined later by
research consortia between academic partners, biotechnology
companies, and large pharmaceutical companies in order to
develop clinical drug candidates. These translational research
approaches and public–private initiatives such as the Innova-
tive Medicines Initiative (IMI) can help to overcome the gap
between basic research and a marketed drug. In particular,
research into new strategies against antibiotic resistance
should benefit from this new drug discovery concept, given
the relevance of this challenge for public health.
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